Cite
Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.
MLA
Bernadou, Guillemette, et al. “Influence of Tumour Burden on Trastuzumab Pharmacokinetics in HER2 Positive Non-Metastatic Breast Cancer.” British Journal of Clinical Pharmacology, vol. 81, no. 5, May 2016, pp. 941–48. EBSCOhost, https://doi.org/10.1111/bcp.12875.
APA
Bernadou, G., Campone, M., Merlin, J., Gouilleux, G. V., Bachelot, T., Lokiec, F., Rezai, K., Arnedos, M., Diéras, V., Jimenez, M., Paintaud, G., & Ternant, D. (2016). Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. British Journal of Clinical Pharmacology, 81(5), 941–948. https://doi.org/10.1111/bcp.12875
Chicago
Bernadou, Guillemette, Mario Campone, Jean‐Louis Merlin, Gruart, Valérie Gouilleux, Thomas Bachelot, François Lokiec, Keyvan Rezai, et al. 2016. “Influence of Tumour Burden on Trastuzumab Pharmacokinetics in HER2 Positive Non-Metastatic Breast Cancer.” British Journal of Clinical Pharmacology 81 (5): 941–48. doi:10.1111/bcp.12875.